Today: 21 January 2026
Subscribe
Browse Category

NASDAQ:RAPT News 21 January 2026

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

New York, Jan 21, 2026, 04:20 EST — Premarket GSK plc’s U.S.-listed shares slipped 1.2% to $47.65 in light premarket trading Wednesday, following the announcement of a $2.2 billion acquisition and changes at its HIV joint venture. The RAPT Therapeutics acquisition marks the first big move by new CEO Luke Miels, coming as investors demand clearer plans from GSK on…
21 January 2026
·····
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

NEW YORK, Jan 20, 2026, 18:51 EST — After-hours Rapt Therapeutics (NASDAQ: RAPT) surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech. GSK’s $58-a-share cash bid values the deal at about a 65% premium over Monday’s close. This is the first big move by CEO Luke Miels, who just took…
21 January 2026
·····

Stock Market Today

  • Danaher Shares Show Momentum but Valuation Remains Premium
    January 21, 2026, 8:09 AM EST. Danaher (DHR) shares gained 7.44% over three months but dropped 3.4% in one-year total returns. Trading around $234.33, the stock's price-to-earnings (P/E) ratio stands at 47.3x, significantly above its fair value P/E of 30.9x and peer average of 32.6x. This premium reflects investor confidence in Danaher's biotechnology and life sciences growth, but raises risks if earnings growth of 15.55% slows or sector valuations compress. Discounted cash flow analysis also indicates shares are expensive relative to future cash flows. Investors face a high valuation hurdle amid mixed momentum and tempered longer-term returns.
Go toTop